Graham Capital Management, L.P. Mersana Therapeutics, Inc. Transaction History
Graham Capital Management, L.P.
- $5.08 Billion
- Q4 2024
A detailed history of Graham Capital Management, L.P. transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Graham Capital Management, L.P. holds 49,724 shares of MRSN stock, worth $24,862. This represents 0.0% of its overall portfolio holdings.
Number of Shares
49,724
Previous 42,417
17.23%
Holding current value
$24,862
Previous $80,000
11.25%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding MRSN
# of Institutions
136Shares Held
101MCall Options Held
77.2KPut Options Held
453K-
Nextech Invest Ag12.1MShares$6.03 Million3.22% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.3MShares$5.66 Million0.76% of portfolio
-
Vr Adviser, LLC New York, NY10.3MShares$5.13 Million2.42% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA8.66MShares$4.33 Million3.35% of portfolio
-
Black Rock Inc. New York, NY8.38MShares$4.19 Million0.0% of portfolio
About Mersana Therapeutics, Inc.
- Ticker MRSN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,169,296
- Market Cap $48.6M
- Description
- Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...